[go: up one dir, main page]

WO2008133618A1 - Procédés et compositions destinés à stimuler et à préserver la croissance osseuse - Google Patents

Procédés et compositions destinés à stimuler et à préserver la croissance osseuse Download PDF

Info

Publication number
WO2008133618A1
WO2008133618A1 PCT/US2007/010267 US2007010267W WO2008133618A1 WO 2008133618 A1 WO2008133618 A1 WO 2008133618A1 US 2007010267 W US2007010267 W US 2007010267W WO 2008133618 A1 WO2008133618 A1 WO 2008133618A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone
agent
subject
parathyroid hormone
calcitonin
Prior art date
Application number
PCT/US2007/010267
Other languages
English (en)
Inventor
Agnes Vignery
Nozer M. Mehta
James P. Gilligan
Kieran P. Murphy
Original Assignee
Unigene Laboratories, Inc.
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigene Laboratories, Inc., Yale University filed Critical Unigene Laboratories, Inc.
Priority to PCT/US2007/010267 priority Critical patent/WO2008133618A1/fr
Priority to CA002685407A priority patent/CA2685407A1/fr
Priority to CN200780052739.5A priority patent/CN101663043B/zh
Priority to AU2007352435A priority patent/AU2007352435B2/en
Priority to EP07776368A priority patent/EP2139507A4/fr
Priority to JP2010506155A priority patent/JP2010526064A/ja
Publication of WO2008133618A1 publication Critical patent/WO2008133618A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the present invention relates generally to methods and compositions for fostering and preserving bone growth in a subject. More particularly, the invention comprises inducing rapid bone formation at locations such as the site of a bone fracture; in areas within the skeleton having diminished bone density; and/or in areas such as the portion of long bones lacking cancellous bone structure and thereafter preserving the new bone thus formed while fostering the growth of additional bone at any such location by, inter alia, providing an internal framework or scaffolding upon which newly produced bone may fasten and grow. Anti-resorption agents may optionally be administered for purpose of reducing the resorption over time of the newly formed bone.
  • the bones of the skeleton are not entirely solid throughout.
  • the outside, i.e., cortical, bone is substantially solid, having only a few small (Haversian) canals.
  • spongy bone Located inwardly from the cortical bone, however, is spongy bone known as cancellous (or trabecular) bone.
  • the cancellous bone is composed of a honeycomb network of trabecular bone defining a plurality of spaces or cavities filled with fluid bone marrow, stem cells and some fat cells.
  • osteoporosis which is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures, particularly of the hip, spine and wrist. Osteoporosis develops where there is an imbalance such that the rate of bone resorption exceeds the rate of bone formation. This is, in part, due to the fact that it can require six months for osteoblasts to rebuild the amount of bone destroyed by osteoclasts in three days. By age fifty-five, for example, the average woman with osteoporosis has already lost thirty percent of her bone mass.
  • Osteoporosis is drastically accelerated during menopause and is the third leading cause of death of women over seventy.
  • the disease also afflicts men, who account for twenty percent of all osteoporosis sufferers.
  • approximately ninety percent of all women and thirty-three percent of all men will suffer from osteoporosis.
  • the ailment causes 1.5 million fractures a year, resulting in annual U.S. health care costs exceeding $18 billion.
  • One in two women and one in eight men over age fifty will have an osteoporosis- related fracture in their lifetime. Of those who suffer from hip fractures, one in five will not survive more than one year.
  • less than ten percent of afflicted persons are treated for osteoporosis with prescription drugs.
  • Such prescription drugs typically include at least one bone augmentation agent.
  • a 'bone augmentation agent' includes but is not limited to bone anabolic agents, and agents that cause elevated blood levels of an endogenous bone anabolic agent to be produced within a subject.
  • Bone augmentation agents such as bone anabolic agents, are well known in the art.
  • Bone anabolic agents commonly include (but are not limited to) parathyroid hormone and various parathyroid hormone fragments, whether amidated or in the free acid form, as well as PTHrP and analogues thereof, Prostaglandin E-2, Bone Morphogenic Proteins, IGF-I, Growth Hormone, fibroblast growth factor TGF and others.
  • agents causing increased expression of endogenous bone anabolic agent include, but again are not limited to, calcilytic agents as well as antibodies to sclerostin.
  • Calcilytic agents typically, but not necessarily, include agents that limit the binding of calcium to its receptor, thereby triggering the release of endogenous parathyroid hormone. Examples of these materials are set forth in United States Patents 6,362,231; 6,395,919; 6,432,656 and 6,521,667, the contents of which are expressly incorporated herein by reference.
  • the method comprises the steps of mechanically inducing an increase in osteoblast activity in one or more 'targeted' bones of a subject in need of additional bone growth, coupled with elevating blood concentration of at least one bone anabolic agent in the subject, wherein the above steps may be performed in any order but wherein they are carried out in sufficient time proximity that the elevated concentration of the bone anabolic agent and the mechanically induced increase in osteoblast activity at least partially overlaps.
  • the above methodology is described, for example, in U.S. patent application Serial No. 11/128,095 file May 11, 2005 and in U.S. Continuation-in-part patent application Serial No. 11/267,987 filed November 7, 2005. The contents of both of these applications are incorporated herein by reference.
  • the method permits specific targeting of particular bones for effects such as repair, strengthening, reshaping and/or remodeling.
  • augmentation agents including but not limited to anabolic agents
  • anti-resorptive agents include (but are not limited to) calcitonins including, for example, human calcitonin, salmon calcitonin, eel calcitonin, elkatonin, porcine calcitonin, chicken calcitonin, SERMS (Selective Estrogen Receptor Modulators), Bisphosphonates, Strontium Ranelate and combinations thereof.
  • an antiresorptive agent is able to protect the newly formed bone.
  • some or all of the new bone formed during the initial growth 'spurt' facilitated due to the presence of the anabolic agent may nevertheless be resorbed by the subject.
  • the effectiveness of the new bone such as increased skeletal strength and/or support, will be compromised.
  • Vertebroplasty and kyphoplasty which are currently in common use in the United States, are surgical procedures for vertebral augmentation that also treat pain associated with vertebral compression fractures. Both of these procedures use x-ray guidance and a transpedicular or parapedicular technique to access the vertebral body for injecting liquid cement therein. The cement then solidifies to augment the weakened and painful vertebra.
  • the simplest procedure is vertebroplasty. This technique is discussed, for example, in United States Patent No. 6,273,916, the contents of which are incorporated herein by reference.
  • a more recent procedure, becoming more common, is kyphoplasty which involves the inflation of a balloon to restore height, whereupon a bone cement is injected into the cavity created by the balloon.
  • PMMA polymethyl methacrylate
  • PMMA is an acrylic bone cement. It is not adhesive and it does not integrate into bone over time, and yet it is remarkably strong. As an analogy, PMMA can act like rebar in cement as used in building construction. The use of PMMA does offer a significant drawback, however, in that PMMA is known to remove or reduce forces that maintain bone density by supplanting the role of trabecular bone structure in its neighborhood, thus removing or reducing the electrical charge that contributes to bone development. Furthermore, the monomer liquid used to dissolve the PMMA powder can be toxic and has been associated with complications such as death and cardiac arrest (See the Nussbaum article).
  • the high compressive strength of PMMA can, in addition, cause adjacent vertebral body fractures by exerting high non compliant forces on the adjacent vertebra, as the vertebral body is too stiff as a result of the injection of the PMMA. These adjacent fractures occur between eight and ten percent of the time.
  • a promising alternative to PMMA are biologically active bone cements or biocompatible polymers.
  • Biologically active bone matrices can obviate some of the difficulties encountered with the use of PMMA.
  • biologically active bone cements can be of lower strength than PMMA, thus causing less stiffness of the vertebral body when they are injected.
  • problems inherent in their use in, for example, vertebral augmentation For example, biologically active bone cements are very difficult to inject, they lack natural radio density, and they do not always integrate well for months or even years. Further, some biologically active bone cements require hours before they solidify and become safe.
  • a biologically active cement useful in vertebral augmentation is calcium phosphate.
  • Calcium phosphate cements are composed of a powder and a liquid solution that dissolves the powder. They are used widely in hip, spine and wrist surgery and also in cranial restriction.
  • the other group belongs to a family that ultimately forms hydroxy apatite, the precursor of bone.
  • peripheral bone cement may be integrated at the endosteal surface of the bone, but bone cement located within the mass of the vertebral body may remain in its unchanged form, a brittle ceramic of low tensile and compressive strength with potential long term negative consequences.
  • an object of the present invention to provide novel and unobvious methods for inducing relatively rapid, targeted bone growth at all locations in need thereof while preserving and augmenting the new bone growth thus obtained.
  • the present invention provides a method of introducing a biocompatible material formed from a biologically active cement or other matrix-forming material within an inner portion of a bone and triggering new bone growth in the region, thereby integrating the cement or other matrix material together with the new bone into the existing bone architecture.
  • the removal of stromal cells via, e.g., irrigation serves as a stimulus for targeted new bone growth
  • a bone augmenting composition such as a bone anabolic agent prolongs the response
  • the matrix-forming material fills in voids where trabecular bone is lacking within an inner portion of the bone and serves as a scaffolding for new bone growth in regions lacking a sufficient amount of such trabecular bone, as well as in areas entirely lacking such trabecular bone.
  • a cyclic treatment paradigm of bone marrow irrigation coupled with administration of an anabolic agent in conjunction with the installation, within an interior portion of a bone, of a biocompatible matrix, followed by anti- resorptive therapy is envisioned in accordance with the present invention.
  • the present invention thus provides, in one embodiment, a method for augmenting bone in a subject in need thereof wherein the method comprises installing within an interior portion of a bone within the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, the scaffold serving as a support for the formation of new bone within the bone interior portion; and, administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject.
  • the invention provides a method for augmenting bone in a subject in need thereof wherein the method comprises mechanically inducing an increase in osteoblast activity within the subject; installing within an interior portion of a bone within the subject where the increase in osteoblast activity has been induced a sufficient amount of a biocompatible material to form a scaffold within the bone interior, the scaffold serving as a support for formation of new bone within the bone interior portion; and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one bone anabolic agent in the subject, wherein the elevation in blood concentration of the bone anabolic agent in the subject and the increase in osteoblast activity therein at least partially overlap in time.
  • the invention is directed to a kit for fostering and preserving bone growth in an interior portion of a bone lacking a sufficient trabecular scaffolding to substantially prevent resorption of new bone formed therein.
  • the kit comprises at least one container having therein at least one biocompatible material adapted for forming an additional amount of scaffolding within the inner bone portion; and, at least one container having therein a bone augmentation agent.
  • the invention is directed to a kit for fostering and preserving bone growth in an interior portion of a bone lacking a sufficient trabecular scaffolding to substantially prevent resorption of new bone formed therein.
  • the kit comprises at least one container having therein at least one biocompatible material adapted for forming an additional amount of scaffolding within the inner bone portion; at least one container having therein a bone augmentation agent; and, a mechanical alteration device for altering contents of a bone marrow cavity in at least one targeted bone.
  • Fig. IA is a section of the mid-shaft of a rat femur following, respectively, 21 and 84 days of treatment.
  • the groups include: (a) control — no bone marrow ablation ("BMX") or anabolic agent, (b) BMX — bone marrow ablation alone; and (c) BMX + PTH — bone marrow ablation plus treatment for either 21 or 84 days with PTH 1-34 NH 2 .
  • the rats were injected with calcein, a fluorescent dye, on 9, 8, 2 and 1 day prior to sacrificing the animals. Calcein becomes incorporated into bone and serves as a measure of bone growth and mineralization;
  • Fig. IB depicts the results from the same groups of animals using the imaging technique known as Micro-CT.
  • This technique provides a high resolution analysis of the femoral shaft marrow cavity from the Control, BMX, and the BMX + PTH 1-34 NH 2 of rats treated with PBS (buffer) or PTH for 21 or 84 days, respectively;
  • Fig. 2 is a flowchart for depicting a method for augmenting bone in accordance with one embodiment of the invention; the procedure entails the administration of a biocompatible matrix material, which may be but is not necessarily a biocompatible bone cement, in conjunction with the administration of a bone augmentation agent such as a bone anabolic formulation;
  • a biocompatible matrix material which may be but is not necessarily a biocompatible bone cement
  • Fig. 3 represents an axial view of a vertebra having an osteoporotic fracture, wherein the vertebra is undergoing administration of a biocompatible matrix material (e.g., a biologically active bone cement) in the performance of one of the steps identified in Fig. 2.
  • a biocompatible matrix material e.g., a biologically active bone cement
  • the biocompatible material is injected into a space devoid of cancellous bone to provide a scaffold for permitting persistent bone formation;
  • Fig. 4 is a representation of the administration of a bone augmentation agent, such as a bone anabolic agent, in the performance of one of the steps identified in Fig. 2.
  • the biocompatible matrix may have an anabolic agent associated with or commingled with the matrix.
  • the anabolic agent may, alternately, be systematically administered to the subject;
  • Fig. 5 is a representation of an axial view of a vertebra with an osteoporosis, wherein the vertebra is undergoing the administration of a biocompatible matrix slurry, in the performance of one of the steps identified in Fig. 2, in accordance with an alternate embodiment of the invention.
  • there is residual cancellous bone that will respond to the combined effects of mechanically inducing an increase in osteoblast activity, e.g., through an irrigation of at least a portion of the marrow cavity, coupled with administration of an anabolic agent, but for the regions lacking trabecular integrity the inclusion of the biocompatible material will fill in the gaps and provide the necessary framework for persistent new bone growth;
  • Fig. 6A illustrates the degree of persistent bone growth achieved after 84 days with the administration of a biocompatible material, in this instance Cementek (Cementek LV, Non- stoichiometric hydroxyapatite prepared from the reaction between the acid and base calcium phosphates in the presence of an aqueous solution. Teknimid, 65500 VIV en Biggore, France) or Pepgen-15 (a high purity anorganic bovine graft material, radiopaque, peptide-enhanced to mimic autogeneous bone. Dentsply Friadent CeraMed Lakewood, CO). All samples were taken from femurs which had BMX performed on them.
  • Cementek cementek LV, Non- stoichiometric hydroxyapatite prepared from the reaction between the acid and base calcium phosphates in the presence of an aqueous solution.
  • Teknimid 65500 VIV en Biggore, France
  • Pepgen-15 a
  • BMX followed by 84 days anabolic agent or PBS (buffer) presented in the first row or BMX followed by insertion of a slurry of biocompatible matrix (Cementek or Pepgen-15) with our without concomitant PTH treatment for 84 days;
  • Fig. 6B depicts the results obtained from the same groups of animals reported in Fig. 6 A using the Micro-CT imaging technique.
  • This imaging technique provides a high resolution analysis of the femoral shaft marrow cavity from the BMX + PBS or PBX +PTH treatments, compared with femurs that had biocompatible materials (Cementek or Pepgen-15) injected into the bone marrow cavity following the step (e.g., ablation) resulting in the inducement of increased osteoblast activity; and
  • Figs. 7 A and 7B illustrate the effect attributable to administration of the anti-resorption agent, Alendronate, in preserving bony tissue formed according to the method of the invention.
  • the following treatment modalities are included: (a) BMX + PTH 1-34 NH 2 for 21 days + PBS (buffer) during days 22-84; (b) BMX + PTH 1-34 NH 2 for 21 days + calcitonin during days 22- 84; (c) BMX + PTH 1-34 NH 2 for 21 days + Alendronate during days 22-84; and (d) BMX + PTH 1-34 NH 2 during days 1-84.
  • Fig. 7B depicts the results from the same groups of animals reported in Fig. 7 A using the Micro-CT imaging technique, which provides a high resolution analysis of the femoral shaft marrow cavity.
  • bone augmentation agent(s) such as a bone anabolic agent (e.g., parathyroid hormone)
  • a bone anabolic agent e.g., parathyroid hormone
  • the invention describes two distinct approaches for preserving new bone in marrow cavities lacking such cancellous bone 'scaffolding', i.e., the cycling of a potent antiresorptive agent, such as a bisphosphonate or the inclusion of one or more biocompatible material such as (but not limited to) a biocompatible bone cement to serve as such scaffolding for supporting the new bone growth and fostering its maintenance.
  • a potent antiresorptive agent such as a bisphosphonate
  • biocompatible material such as (but not limited to) a biocompatible bone cement
  • biocompatible materials for forming a scaffolding within a targeted bone for facilitating bone growth according to the present invention
  • biologically active materials are commonly referred to hereafter as “biocompatible materials” and/or “biologically active materials”.
  • This term is herein defined to include not only bone cements (including biocompatible bone cements) but also alternate materials, such as polymers, gels and/or foams, slurries or suspensions of calcium phosphate or hydroxyapatite now know or subsequently discovered, which provide the capability for forming the required scaffolding within the interior portion of the bone.
  • Bone resorption in the diaphysis of long bones lacking cancellous bone architecture has been found to occur even in those instances where the administration of, e.g., bone anabolic agent is coupled with the inducement of increased osteoblast activity in a bone targeted for such additional bone growth, which technique is described, for example in application Serial No. 11/128,095 filed May 11, 2005 and application Serial No. 11/267,987 filed November 7, 2005 which are incorporated above by reference into this application.
  • treatment with PTH for 21 days extends the bone- formation phase that follows BMX and leads to additional bone formation.
  • bone resorption may be slowed and/or reduced via the administration of an anti-resorptive agent, such as calcitonin and/or alendronate
  • an anti-resorptive agent such as calcitonin and/or alendronate
  • the present invention provides methods and compositions for achieving rapid and sustained targeted bone growth, coupled with a desirable reduction in loss of the new bone thus produced due to factors such as resorption in particular targeted areas of bone.
  • the invention is directed to a method for augmenting a bone, including (but not limited to) long bones, e.g., the femur and humerus, as well as smaller bones, such as the vertebrae, of an individual.
  • 'augment' or 'augmentation' means to increase the amount and/or density of bony tissue contained within the bone, while correspondingly reducing or preventing entirely if possible the subsequent accelerated resorption of the newly formed bony tissue produced with the use of the method.
  • the above is accomplished with the use of a method which comprises, in one step, imparting a biologically active material such as a bone cement into an interior portion of the bone to be augmented.
  • a biologically active material such as a bone cement
  • the biocompatible material including but not limited to a bone cement, can be delivered in a radiographically controlled way or by open surgical application.
  • Various biocompatible materials which are effective for use in the method of the present invention are described more fully below.
  • the biologically active material associates with the trabecular bone structure located in an interior portion of a 'target' bone to form a scaffolding therein which serves as a framework for permitting additional bone growth at that location, so as to permit restoration of normal bone functionality and strength in a desired area, e.g., an area where a fracture has occurred or an area at risk for a future fracture due, e.g., to a loss of bone density.
  • a desired area e.g., an area where a fracture has occurred or an area at risk for a future fracture due, e.g., to a loss of bone density.
  • the cement and newly formed bone become integrated into the existing bone structures. This is advantageous as normal trabecular bone has sophisticated weight distribution, compression shear strength and regenerative properties that cannot be reproduced with, for example, the use of bone cements alone.
  • augmentation of vertebral bone is frequently relied upon as a means of exemplifying the invention.
  • the invention is not to be construed as being limited to use only with vertebral bones. That is, as indicated above other bones can be augmented by means of the methodology described herein, including, but not limited to, the hip, the proximal femoral neck, the distal radius, the proximal humerus, the calcaneus, a rib or ribs, the tibia, and the sacrum.
  • a vertebra is indicated generally at 50.
  • Vertebra 50 has an osteoporotic fracture or a spinal deformity and exemplifies one type of bone and a corresponding condition (i.e., a fracture) that can be treated with the use of method 100.
  • step 110 is performed which comprises the administration of the biologically active material following irrigation for removing stromal cells.
  • the introduction into the bone of the biocompatible material can serve as the method for removing the stromal cells , but the preferred method involves a preliminary irrigation to efficiently removal stromal cells bone marrow.
  • a vertebra such as vertebra 50
  • administration of the biocompatible material is typically performed using vertebroplasty or kyphoplasty.
  • vertebra 50 is shown undergoing a vertebroplasty to effect step 110.
  • the figure thus shows a vertebroplasty needle 54 inserted along a transpedicular approach, with the tip of needle 54 positioned within the vertebral body 58.
  • the irrigation and removal of stromal cells can be accomplished using the same needle or a specifically modified needle that provides a better method for irrigation and collection of the stromal cells.
  • step 110 on vertebra 50 can be effected using any presently known or future contemplated vertoblasty techniques, using appropriate or desired needles, image guidance modalities and the like.
  • the type of biocompatible material (e.g., bone cement) 62 will influence such choices and will also be selected as a means of complementing the choices used to effect step 120.
  • the administration of the biocompatible material and the augmentation agent may be achieved via separate injections into the vertebral body.
  • the cement or other biocompatible matrix material maybe injected into one pedicle of the vertebral body and the bone augmentation agent could be injected into the other pedicle or through an ipsilateral approach through the same pedicle as the biocompatible material or it may, instead, be mixed therewith.
  • the anabolic agent can be administered systemically as well.
  • the biocompatible material is, in one embodiment of the invention, at least one biologic bone cement, also referred to herein as a biologically active bone cement.
  • Suitable biocompatible materials include, but are not limited to calcium phosphate, calcium hydroxyapatite, calcium sulphate, calcium aluminate a bone morphogenic protein, polymers, fibrinogen, synthetic fibrins, collagen gels, collagen plus hydroxyapatite suspensions and various combinations thereof.
  • Alpha-BSM Bone Substitute Material comprising a synthetic bioresorbable bone substitute material engineered the chemical composition and crystalline structure of the crystalline structure of bone, sold by ETEX Corporation, Cambridge MA
  • Cortoss Synthetic Cortical Bone comprised of three di-functional cross-linked resins delivered as two mix-on-demand pastes, sold by Orthovita Corp., Malverne PA
  • Cementek LV a non-stoichiometric hydroxyapatite prepared from the reaction between acid and basic calcium phosphates in the presence of an aqueous solution, sold by Teknimid located at 65500 VIC en Bigorre, France
  • one or more cements provides, for example, short term stability and/or pain relief, while another provides long term integration and new bone development.
  • the selection of the biomaterial will be site specific. For example, the biocompatible material used to prevent hip fractures will be different from the biomaterial used to support vertebrae during vertoplasty. Additionally, the biocompatible material, in most instances, will not be used in an "off the shelf condition. That is, its formulation and/or physical state will be modified as necessary for a particular application, for example, by conversion into a suspension, foam or gel and/or by modifying factors such as the concentration, size, shape, etc. of the solid particles of which these materials are comprised.
  • Enhanced bone cements are also useful in the invention and include a bone cement as well as an augmentation agent.
  • the bone cement used in such enhanced bone cements include Cementek and Cementek LV
  • examples of the augmentation agent used in these enhanced bone cement include (but are not limited to) insulin related growth factor ("IGF"), rhPTH, GH, anabolic vitamin D analogs, low density lipoprotein receptor related protein 5 (LRP5) activator, or an inhibitor of sclerostin binding to LRP5, an activator of non genomic estrogen signaling (ANGELS), a bone morphogenic protein, a growth hormone releasing factor (GHRF) hepatcyte growth factor (HGF) calcitonin gene related peptide (CGRP) parathyroid related peptide (PTHrP) Transforming growth factor (TGF) and/or combinations thereof.
  • IGF insulin related growth factor
  • rhPTH rhPTH
  • GH anabolic vitamin D analogs
  • LRP5 low density lip
  • the embodiment as described herein additionally constitutes a further step (i.e., performed in conjunction with the installation within a target bone of the biologically active bone cement), which involves the administration to the subject of a bone augmentation agent.
  • a bone augmentation agent will be administered to the subject on, e.g., a daily basis for up to six (6) months.
  • the augmentation agent such as a bone anabolic composition for example, assists by facilitating or otherwise enhancing the growth of trabecular bone upon the surface of a scaffolding formed by the bone cement and thereafter resulting in a diminished degree of bone resorption, at least in comparison to methods using either the bone cement or the bone augmentation agent by themselves.
  • the bone augmentation agent can be administered in any suitable manner, including by injection, intravenously ( 1 TV"), peroral ("PO"), transdermally, transnasally or transrectally and at any suitable time before, during or after the installation of the bone cement within the interior of the bone.
  • 1 TV intravenously
  • PO peroral
  • transdermally transnasally or transrectally and at any suitable time before, during or after the installation of the bone cement within the interior of the bone.
  • the agent may be administered systemically or else directly to a location where the bone cement is introduced.
  • the timing and method of administration of the bone augmentation agent would be well understood by one having ordinary skill in this field of art. That is, the steps in method 100 can be performed in a different order than shown, or simultaneously.
  • the bone augmentation agent can be, as indicated above, an anabolic bone agent or any other agent that promotes the integration of the injected cement.
  • the bone augmentation agent has been found, as indicated above, to produce a joint effect with that provided by the bone cement which helps to convert the biologically active bone cement to actual bone more rapidly then is usually achieved in the poor quality trabecular bone of the osteoporotic patient. In the absence of the bone anabolic agent the bone cement can be resorbed, thus diminishing its effectiveness.
  • Some useful bone augmentation agents are exemplified below.
  • a sufficient amount of one preferred bone anabolic agent i.e., PTH[I -34]NH 2
  • PTH[I -34]NH 2 is administered to patient 68 via, for example, a needle 72 to achieve, and maintain, a pulsatile blood concentration thereof in a subject of between about 50 and about 350 pg/ml, preferably between about 100 and about 200 pg/ml, and most preferably between about 150 pg/ml.
  • the blood concentration of the PTH[I -34]NH 2 in the patient is raised to its preferred level by no later than seven days following the performance of step 110.
  • an appropriate dosage of PTH[I -34]NH 2 is determined to achieve the desired blood concentrations.
  • the dosage can, though need not necessarily be, in the range of between about 10 to about 200 micrograms (“ ⁇ g") > given once per day, more preferably between about 20 and about 100 ⁇ g per dose and more preferably between about 20 and about 50 ⁇ g per dose, or most preferably between about 20 and about 40 ⁇ g per dose given once per day.
  • FIG. 5 a vertebra is indicated generally at 50a.
  • Vertebra 50a also has an osteoporotic fracture and exemplifies one type of bone (a vertebra) and a corresponding condition (fracture) that can be treated using method 100.
  • step 110 and step 120 are performed substantially simultaneously.
  • FIG. 5 shows an enhanced or derivatized bone cement 62a.
  • FIG. 2 shows a vertebroplasty needle 54a inserted along a transpedicular approach with the tip of needle 54a positioned within the vertebral body 58a.
  • Needle 54a is also shown expressing the enhanced bone cement 62a within vertebral body 58a.
  • a biologically active bone cement hereinafter also referred to as, a "biologic material”
  • an orally administered bone augmentation agent is used to assist integration of the cement from its injected state into a material that is akin to normal native bone by promoting bony growth on, in and/or around the particles of the cement such that the additional bone thus formed is caused to grow more rapidly, with a markedly lesser degree of resorption that methods relying upon either a bone augmentation agent or a cement used by itself.
  • Another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and a nasally administered augmentation agent is used to assist integration and transformation of the biologic material from the injected state into a material that is akin to normal native bone as described above.
  • Still another example of this embodiment includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and a transdermally administered augmentation agent is used to assist in the integration and transformation of said biologic material from its injected state into a material that is akin to normal native bone.
  • An additional example involves a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and an injected augmentation agent is used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • a still further example of this embodiment includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and parathyroid hormone ("PTH") is used to assist in the integration and transformation of the biologic material from its injected state into a material that is akin to normal native bone.
  • PTH parathyroid hormone
  • Another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and recombinant parathyroid hormone ("rhPTH”) is used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • rhPTH recombinant parathyroid hormone
  • a further example of this embodiment of the invention includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and calcitonin is used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • Still another example of this embodiment includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and growth hormone is used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • An additional example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and insulin related growth factor is used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • a still further example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a bone cement composed of Calcium phosphate is delivered into the bone and a integration stimulant used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • Another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a bone cement composed of Calcium hydroxyapatite is delivered into the bone and an integration stimulant used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • Still another example of the invention includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a bone cement composed of Calcium sulphate is delivered into the bone and an integration stimulant used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • Another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a bone cement composed of Calcium aluminate is delivered into the bone and an integration stimulant used to assist its integration and trans formation from its injected state into a material that is akin to normal native bone.
  • An additional example of this embodiment of the invention includes a method of treating an osteoporotic fracture in the body of an individual in need thereof where a bone cement composed of bone morphogenic protein is delivered into the bone and a integration stimulant used to assist its integration and transformation from its injected state into a material that is akin to normal native bone.
  • Another example includes a method of treating a vertebral fracture in an individual in need thereof using cement that has an insulin related growth factor (“IGF") embedded therein, and which is delivered into the vertebrae.
  • the method also includes administering calcitonin or PTH or other bone augmentation accelerant using any suitable delivery mechanism, such as orally, nasally, injection, transdermally etc.
  • Still another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and recombinant parathyroid hormone ("rhPTH”) is also delivered into the bone with the cement as an accelerant of local bone growth and cement integration and transformation from its injected state into a material that is akin to normal native bone.
  • rhPTH parathyroid hormone
  • An additional example of this embodiment of the invention includes a method of treating an osteoporotic fracture in the body of an individual in need thereof wherein a biologic material is delivered into the bone and recombinant parathyroid hormone ("rhPTH") and Insulin related growth factor are also delivered into the bone with the cement as an accelerant of local bone growth and cement integration and transformation from its injected state into a material that is akin to normal native bone.
  • rhPTH parathyroid hormone
  • Insulin related growth factor are also delivered into the bone with the cement as an accelerant of local bone growth and cement integration and transformation from its injected state into a material that is akin to normal native bone.
  • Another example includes a method of treating an osteoporotic fracture in the body of an individual in need thereof where a biologic material is delivered into the bone and recombinant parathyroid hormone ("rhPTH") and Insulin related growth factor are also delivered into the bone with the cement as an accelerant of local bone growth and cement integration and transformation from its injected state into a material that is akin to normal native bone.
  • rhPTH parathyroid hormone
  • Insulin related growth factor are also delivered into the bone with the cement as an accelerant of local bone growth and cement integration and transformation from its injected state into a material that is akin to normal native bone.
  • Oral/TV or some other method of systemic bone anabolic stimulant is delivered to the patient for a broader increase in global bone density.
  • the above-described examples of the invention may include an additional step altering the contents of the bone marrow cavities in the bones so treated so as to remove all or a portion of the stromal cells from the cavity.
  • the administration of the biocompatible material may serve this purpose by forcing the cells from the marrow cavity, or else an alternate method, such as irrigation, may instead be used for the identical purpose.
  • Fig. 7A illustrates that bone formed in the marrow cavity in response to bone marrow ablation (BMX) followed by 21 day treatment with PTH, is protected by treatment with calcitonin or alendronate given for the next 63 days, as illustrated by the fluorescent signal from calcein that has been incorporated into the mineralizing bone.
  • Alendronate is a powerful anti-resorptive agent and, at the dose administered, it had a greater protective effect on the newly synthesized bone.
  • the ablated marrow cavity of femurs from rats treated for 84 days with PTH contains a minimum amount of fluorescent label. Calcein was injected on days 9, 8, 2 and 1 before sacrifice of the animals.
  • calcitonin and alendronate protect the bone that forms in response to marrow ablation (BMX) and 21 day treatment with PTH.
  • BMX marrow ablation
  • Fig. 7 A the bone formed in the marrow cavity in response to marrow ablation followed by 21 day treatment with PTH is protected by calcitonin or alendronate given for the next 63 days, as demonstrated by the fluorescent signal from calcien that has been incorporated into mineralizing bone.
  • the ablated marrow cavity of femurs from rats treated for 84 days with PTH no longer contains fluorescent labels.
  • Fig. 7B illustrates the results obtained by Micro-CT analysis of the bone formed in the marrow cavity in response to marrow ablation followed by 21 day treatment with PTH followed by subsequent treatment with either of the anti-resorptive drugs calcitonin or alendronate, for an additional 63 days.
  • Calcitonin and to a greater extent, alendronate, protects the bone that forms in response to marrow ablation and 21 day treatment with PTH.
  • the ablated marrow cavity of the diaphysis of femurs from rats treated for 84 days with PTH no longer contains radio-dense bone.
  • the method of the invention is utilized with a human subject.
  • the invention additionally comprises veterinary applications.
  • the invention includes an additional step of mechanically inducing an increase in osteoblast activity within the subject to be treated, which inducement is carried out in conjunction with the introduction of a biocompatible material such as a bone cement and the administration of a bone augmentation agent, such as a bone anabolic agent, to said subject as described above.
  • a biocompatible material such as a bone cement
  • a bone augmentation agent such as a bone anabolic agent
  • an antiresorptive agent may be administered to the subject for a duration and at a concentration sufficient to further reduce resorption of the bone formed due to the synergistic interaction among the various method steps.
  • An additional factor preventing such resorption and thus preserving the additional bone growth achieved through the use of the method of the invention is the presence of the bone cement, which acts as a 'scaffold' or support to permit further growth extending therefrom. Once an adequate amount of bone has been formed an anti-resorptive agent can be administered to protect the bone that has been synthesized.
  • the mechanical inducement may be, but is not necessarily, achieved through the use of a method which comprises mechanically altering the contents of a bone marrow cavity located within the bone where it is desired to foster and preserve such additional bony growth.
  • a method which comprises mechanically altering the contents of a bone marrow cavity located within the bone where it is desired to foster and preserve such additional bony growth.
  • Various methods for achieving such an alteration of the bone marrow cavity contents are described below.
  • Inducement of bone growth may include, for example, generating new or additional bone at locations where such bone growth is not presently taking place and/or stimulating the growth (i.e., increasing the rapidity thereof) of bone which is already in the process of formation.
  • the inducement of bone growth takes place due to the combined effects of (1) the mechanical inducement of osteoblast activity in the subject coupled with (2) an elevation in the blood concentration of at least one bone anabolic agent therein.
  • the bone described as being formed by the process of the invention is not limited solely to trabecular bone and should also be taken to include any one or more of the following additional 'types' of bone: compact, cortical and /or lamellar bone.
  • Mechanical inducement of an increase in osteoblast activity may be obtained, in a preferred embodiment of the invention, by a process of bone marrow irrigation and ablation.
  • the bone marrow irrigation or mechanical process leads to the formation of a blood clot within the bone marrow cavity which, through a cascade of biochemical reactions, contributes to increasing osteoblast activity in the subject.
  • the increased osteoblast activity may alternately be obtained by coupling the mechanical inducement with an additional form of inducement such as biochemical inducement.
  • biochemical inducement may be obtained by administering to the subject, for example, a quantity of a blood factor such as Factor ("F") VII, fibrinogen or fibrin, Factor Vila or a combination thereof.
  • F Factor
  • tissue thromboplastin tissue factor
  • This complex (FVEl/FVIIa + Thromboplastin) initiates a sequence of events which leads to activation of the coagulation cascade ultimately leading to fibrin deposition and platelet activation.
  • This complex sequence of events may contribute in part to the stimulation of osteoblasts in the bone marrow.
  • Factors VII and Vila are commercially available from, for example, Novo Nordisk.
  • the increase in osteoblast activity obtained with the use of the method of the invention may be due to a variety of factors including, but not necessarily limited to: (1) osteoblast differentiation, i.e., the production of additional osteoblasts, (2) increasing the activity and/or effectiveness of osteoblasts which are already present in inducing bone formation in the subject, and (3) a combination thereof.
  • the increase in osteoblast activity would include all of the above-noted functions.
  • the method additionally comprises "targeting" one or more specific bones of the subject for inducement of bone growth. This targeting is accomplished by mechanically altering the contents of a bone marrow cavity within each targeted bone so as to induce the increased osteoblast activity therein.
  • the method of the invention is thus useful not only for bone repair, i.e., as in the case of a bone fracture due to trauma, but also for strengthening bone in a site-specific manner in the case of individuals shown by Dual Energy X-Ray Absorptiometry ("DEXA") or other techniques to require an increase in bone mass and/or density to prevent bone fractures (e.g., such as those afflicted with osteoporosis), or who suffer due to bone weakness from chronic pain attributable to conditions such as vertebral crush.
  • the method of the invention additionally serves to provide (and retain) new bone needed to serve as an anchor for prostheses such as artificial hips, knees and shoulders and/or for implants such as dental implants.
  • the new bone growth can be targeted to bones at risk of fracture to improve strength and thereby reduce the risk of fracture.
  • the bone anabolic agent may be administered to the subject contemporaneous with the mechanical inducement of osteoblast activity (whether by increased osteoblast formation and/or by increased bone formation by pre-existing osteoblasts), which mechanical inducement may be achieved, e.g., by alteration of the bone marrow cavity.
  • marrow and/or other components of the marrow cavity is/are removed under pressure (e.g., by altering the relative pressure within versus without the marrow cavity), e.g., by irrigating the cavity and removing the stromal cells.
  • the bone anabolic agent is administered subsequent to such mechanical inducement.
  • the bone anabolic agent may be administered prior to mechanical inducement such that elevated levels of bone anabolic agent are already present at the time of mechanical inducement, which levels may then be maintained or continued intermittently for an extended period thereafter.
  • the bone anabolic agent may be administered orally, intravenously, intramuscularly, subcutaneously, via implant, transmucosally, transdermally, rectally, nasally, by depot injection or by inhalation and pulmonary absorption, hi another embodiment the bone anabolic agent may be administered once as a time release formulation, a plurality of times, or over one or more extended periods. It is preferred that elevated blood levels of the anabolic agent be maintained at least intermittently for between about 14-365 days, and more preferably for between about 30-180 days, post-mechanical induction.
  • Intermittent administration of parathyroid hormone e.g., PTH[l-34]-NH2
  • PTH[l-34]-NH2 could occur once daily or once weekly resulting in peaks of blood concentration that return to baseline levels between doses, but nevertheless result in periodic elevated blood levels of a bone anabolic agent in a manner that overlaps the elevated osteoblast activity that is initially induced mechanically, although thereafter sustained, at least in part, by the anabolic agent.
  • the anabolic agent is selected from the group consisting of a parathyroid hormone (PTH), anabolic Vitamin D analogs, a low-density lipoprotein receptor- related protein 5 (LRP5) activator, or an inhibitor of sclerostin binding to LRP5, an activator of non-genomic estrogen-like signaling (ANGELS), a bone morphogenic protein (BMP), an insulin- like growth factor (IGF), a fibroblast growth factor (FGF), sclerostin, leptin, a prostaglandin, a statin, strontium, a growth hormone, a growth hormone releasing factor (GHRF), hepatocyte growth factor (HGF), calcitonin gene related peptide (CGRP), parathyroid hormone related peptide (PTHrP), transforming growth factor (TGF)-PGE-2 and stable analogs thereof and combinations thereof.
  • the term parathyroid hormone includes, but is not limited to natural parathyroid hormone, a trun
  • the bone anabolic agent is truncated PTH[I -34] in the free acid form.
  • This material is commercially available in an FDA-approved pharmaceutical formulation from Eli Lilly & Co. under the trade name Forteo® (teriparatide).
  • Other useful bone anabolic agents for use with the invention include, but are not limited to, an amidated truncate of natural parathyroid hormone, PTH[l-30]NH 2 , PTH[1-31]NH 2 , PTH[1-32]NH 2 , PTH[1-33]NH 2 , PTH[1-34]NH 2 and combinations thereof.
  • the bone anabolic agent is PTH[1-34]NH 2 .
  • a sufficient amount of the preferred truncated parathyroid hormone is administered to the subject to achieve, and thereafter maintain, a pulsatile blood concentration thereof in the subject of between about 50 and 350 pg/ml, preferably between about 100 and 200 pg/ml, and most preferably about 150 pg/ml.
  • the blood concentration of the parathyroid hormone in the subject is raised to its preferred level by no later than 7 days following mechanical alteration of the contents of the bone marrow cavity.
  • an appropriate dosage of the PTH bone anabolic agent must be calculated to achieve the above-indicated blood concentrations, hi the case of injectable formulations, for example, the dose (in pure weight of the active hormone) given to, for example, a human subject, may be that taught in the literature relating to the bone anabolic activity of these various agents.
  • Such dose if given by the parenteral route, may, but does not necessarily, range between about 10-200 ⁇ g, given once per day, more preferably between about 20-100 ⁇ g per dose and most preferably between about 20-50 ⁇ g per dose.
  • Dosage levels of injectable formulations comprising bone anabolic agents other than the above-described parathyroid hormone-based agents would be consistent with the known blood levels required to evoke an anabolic response in man.
  • the mechanical induction of osteoblast activity is accomplished by inserting, into a bone marrow cavity of a bone targeted for enhanced bone formation, an object configured or adapted to physically alter the contents of the cavity and thereby to stimulate the osteoblast activity within the cavity.
  • the mechanical alteration may include removal of at least a portion of the cavity contents.
  • a suitable method is to irrigate the bone marrow cavity with a solution to remove stromal cells.
  • the application of the biocompatible material may be used to remove bone marrow cells and, thereby, for inducing osteoblast activity.
  • the method of the invention additionally comprises administering to the subject an antiresorptive agent for a time and at a concentration sufficient to substantially prevent resorption of the new bone produced due to the osteoblast activity.
  • the antiresorptive agent may be administered contemporaneous with the administration of the bone anabolic agent.
  • the antiresorptive agent is administered subsequent to the administration of the bone anabolic agent.
  • the administration of the antiresorptive agent may be commenced during administration of the bone anabolic agent and such administration may then be continued beyond the termination of administration of the bone anabolic agent.
  • a single agent may by administered having both bone anabolic and antiresorptive properties.
  • examples of such materials include, but are not limited to estrogen, strontium ranalate and selective estrogen receptor modulators (SERMS).
  • the antiresorptive agent may be a calcitonin selected from the group consisting of human calcitonin, salmon calcitonin ("sCT"), eel calcitonin, elkatonin, porcine calcitonin, chicken calcitonin, calcitonin gene related peptide (CGRP) and combinations thereof.
  • sCT salmon calcitonin
  • eel calcitonin el calcitonin
  • CGRP calcitonin gene related peptide
  • the antiresorptive agent is salmon calcitonin.
  • Blood levels of calcitonin, when used as the antiresorptive agent preferably range between about 5-500 pg/ml, more preferably between about 10-250 pg/ml and most preferably 20-50 pg/ml.
  • human dosage levels of the subject calcitonin agents necessary to achieve the above blood levels may be those taught in the literature relating to the use of these materials as anabolic agents. Such dose may, but does not necessarily, range between about 5-200 ⁇ g given once per day, more preferably between about 5- 50 ⁇ g and most preferably 8-20 ⁇ g by weight of the pure drug, administered daily. Salmon calcitonin (sCT) administered by alternate routes, i.e., by nasal or oral administration, would require higher dosages than those discussed above. Alternately, a variety of additional antiresorptive agents (i.e., other than the calcitonins) are useful with the method of the present invention.
  • HRT agents such as selective estrogen receptor modulators (SERMS), bisphosphonates, cathepsin-K inhibitors, strontium ranalate and various combinations thereof.
  • additional antiresorptive agents include, but are not limited to, (1) Premarin® available from Wyeth Laboratories, which includes estrogen as the active ingredient. A typical accepted dosage is one 0.625 mg tablet daily; (2) Actonel® available from Proctor & Gamble, which includes, as its active ingredient, risedronate sodium. A typical accepted dosage is one 5 mg tablet daily or one 35 mg tablet weekly; (3) Evista® sold by Eli Lilly & Co. which includes raloxifene HCl as the active ingredient.
  • SERMS selective estrogen receptor modulators
  • a typical accepted dosage of this formulation is one 60 mg tablet taken daily; and (4) Fosamax® available from Merck Pharmaceuticals, which includes alendronate as the active ingredient. Typical dosages of this material are 10 mg/day or 70 mg/week. Additional bisphosphonates include Actonel ® (Proctor Gamble Aventis), Ibandronate ® (GSK Roche) and Zolendronate ® (Novartis).
  • dosages herein refer to the weight of the active compounds unaffected by pharmaceutical excipients, diluents, carriers or other ingredients, although such other ingredients are typically included in the variety of dosage forms useful in the method of the invention.
  • Any dosage form i.e., capsule, tablet, injection or the like
  • the terms "excipient”, “diluent” or “carrier” include such non-active ingredients as are typically included, together with active ingredients, in the industry.
  • typical capsules, pills, enteric coatings, solid or liquid diluents or excipients, flavorants, preservatives, or the like are included.
  • the attending clinician should monitor individual patient response, and adjust the dosage accordingly.
  • the antiresorptive agent may be administered orally, intravenously, intramuscularly, subcutaneously, via implant, transmucosally, rectally, nasally, by depot injection, by inhalation and pulmonary absorption or transdermally. Moreover, the antiresorptive agent may be administered once, a plurality of times, or over one or more extended periods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
  • Surgical Instruments (AREA)

Abstract

La présente invention concerne un procédé d'augmentation osseuse chez un le sujet nécessitant, consistant à mettre en place, dans une partie interne d'un os du sujet, une quantité suffisante de matériau biocompatible afin de former une structure d'échafaudage à l'intérieur de l'os, cette structure servant de support pour la formation de nouveau tissu osseux dans la partie interne de l'os, et à administrer au sujet une quantité suffisante d'au moins un agent de croissance osseuse pour d'augmenter la concentration sanguine d'au moins un agent anabolique chez le sujet. Le procédé peut également consister à administrer au sujet au moins un agent anti-résorption en une quantité suffisante pour prévenir sensiblement la résorption de l'os nouvellement formé. Dans un autre mode de réalisation, le procédé peut aussi comprendre une étape consistant à induire mécaniquement une élévation de l'activité des ostéoblastes chez le sujet, l'augmentation de la concentration sanguine d'agent anabolique et la hausse de l'activité ostéoblastique se superposant au moins partiellement dans le temps.
PCT/US2007/010267 2007-04-27 2007-04-27 Procédés et compositions destinés à stimuler et à préserver la croissance osseuse WO2008133618A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/US2007/010267 WO2008133618A1 (fr) 2007-04-27 2007-04-27 Procédés et compositions destinés à stimuler et à préserver la croissance osseuse
CA002685407A CA2685407A1 (fr) 2007-04-27 2007-04-27 Procedes et compositions destines a stimuler et a preserver la croissance osseuse
CN200780052739.5A CN101663043B (zh) 2007-04-27 2007-04-27 促进和保持骨生长的方法和组合物
AU2007352435A AU2007352435B2 (en) 2007-04-27 2007-04-27 Methods and compositions for fostering and preserving bone growth
EP07776368A EP2139507A4 (fr) 2007-04-27 2007-04-27 Procédés et compositions destinés à stimuler et à préserver la croissance osseuse
JP2010506155A JP2010526064A (ja) 2007-04-27 2007-04-27 骨組織の成長の育成および保存のための方法および組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/010267 WO2008133618A1 (fr) 2007-04-27 2007-04-27 Procédés et compositions destinés à stimuler et à préserver la croissance osseuse

Publications (1)

Publication Number Publication Date
WO2008133618A1 true WO2008133618A1 (fr) 2008-11-06

Family

ID=39925939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/010267 WO2008133618A1 (fr) 2007-04-27 2007-04-27 Procédés et compositions destinés à stimuler et à préserver la croissance osseuse

Country Status (6)

Country Link
EP (1) EP2139507A4 (fr)
JP (1) JP2010526064A (fr)
CN (1) CN101663043B (fr)
AU (1) AU2007352435B2 (fr)
CA (1) CA2685407A1 (fr)
WO (1) WO2008133618A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101966348A (zh) * 2010-09-21 2011-02-09 中国科学院深圳先进技术研究院 掺锶羟基磷灰石胶原复合材料及其应用和制备方法
EP3345607B1 (fr) 2006-12-29 2022-10-26 Ossifi-Mab LLC Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573558B (zh) * 2015-09-30 2017-03-11 愛派司生技股份有限公司 一種含具有複數螺紋區之骨螺釘的骨板組

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (fr) * 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
US20050256047A1 (en) * 2004-05-14 2005-11-17 Agnes Vignery Method for fostering bone formation and preservation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724897D0 (en) * 1987-10-23 1987-11-25 Downes S Material
CN1427700B (zh) * 2000-04-05 2010-04-21 科丰有限公司 治疗骨折和/或病骨的方法和装置
CA2425612A1 (fr) * 2000-10-16 2002-04-25 Brian R. Genge Ciment biocompatible contenant des nanoparticules reactives de phosphate de calcium et procedes de fabrication et d'utilisation d'un tel ciment
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
CN1294885C (zh) * 2001-06-05 2007-01-17 江苏阳生生物工程有限公司 人体骨组织生物工程支架制品及其制备方法和用途
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
CA2460843A1 (fr) * 2001-09-21 2003-03-27 Stryker Corporation Agents porogenes pour ciments orthopediques
EP1467748A1 (fr) * 2002-01-17 2004-10-20 Board Of Regents The University Of Texas System Stimulation de la croissance osseuse et de la formation du cartilage au moyen de derives peptidiques de la thrombine
SE0300620D0 (sv) * 2003-03-05 2003-03-05 Bone Support Ab A new bone substitute composition
US7175858B2 (en) * 2004-07-26 2007-02-13 Skeletal Kinetics Llc Calcium phosphate cements and methods for using the same
US20060089723A1 (en) * 2004-10-25 2006-04-27 Murphy Kieran P Method for bone augmentation
WO2006072622A2 (fr) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Matrices enrichies pour la reparation des fractures osseuses
JP2006263184A (ja) * 2005-03-24 2006-10-05 Gc Corp 骨セメント注入充填方法及び骨セメント注入充填用漏洩防止袋
EP1879608A4 (fr) * 2005-05-11 2009-11-11 Unigene Lab Inc Methode pour stimuler la formation et la preservation des os
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (fr) * 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
US20050256047A1 (en) * 2004-05-14 2005-11-17 Agnes Vignery Method for fostering bone formation and preservation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2139507A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345607B1 (fr) 2006-12-29 2022-10-26 Ossifi-Mab LLC Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise
US11807681B2 (en) 2006-12-29 2023-11-07 Ossifi-Mab Llc Methods of altering bone growth by administration of Sost or Wise antagonist or agonist
US11891438B2 (en) 2006-12-29 2024-02-06 Ossifi-Mab Llc Methods of altering bone growth by administration of Sost or Wise antagonist or agonist
CN101966348A (zh) * 2010-09-21 2011-02-09 中国科学院深圳先进技术研究院 掺锶羟基磷灰石胶原复合材料及其应用和制备方法

Also Published As

Publication number Publication date
AU2007352435B2 (en) 2012-01-19
AU2007352435A1 (en) 2008-11-06
JP2010526064A (ja) 2010-07-29
CN101663043B (zh) 2014-03-12
CN101663043A (zh) 2010-03-03
EP2139507A1 (fr) 2010-01-06
EP2139507A4 (fr) 2012-06-06
CA2685407A1 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
EP1881793B1 (fr) Implant osseux
US5824087A (en) Bone regeneration
US7776826B2 (en) Method for fostering bone formation and preservation
AU2005244829B2 (en) Method for fostering bone formation and preservation
US20110268820A1 (en) Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
KR20030072399A (ko) 골괴사 치료용 및 골괴사 발현의 위험이 있는 환자의처리용 약제
US8852240B2 (en) Methods and compositions for fostering and preserving bone growth
AU2007201464B2 (en) Method for bone augmentation
Tekin et al. Effects of alendronate on rate of distraction in rabbit mandibles
AU2007352435B2 (en) Methods and compositions for fostering and preserving bone growth
EP1879608A1 (fr) Methode pour stimuler la formation et la preservation des os
Song et al. Methods to Enhance Bone Formation in Distraction Osteogenesis
AU2005331907B2 (en) Method for fostering bone formation and preservation
CA2582846A1 (fr) Methode d'augmentation de la matiere osseuse
CN101052410A (zh) 促进骨形成和保持的方法
WO2007012841A2 (fr) Composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780052739.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07776368

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007352435

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007352435

Country of ref document: AU

Date of ref document: 20070427

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010506155

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2685407

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007776368

Country of ref document: EP